Kiniksa Pharmaceuticals International, plc KNSA Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's additional paid-in capital?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported additional paid-in capital of $1.05B in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's additional paid-in capital changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's additional paid-in capital increased by 7.8% year-over-year, from $970.24M to $1.05B.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's additional paid-in capital?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's additional paid-in capital has grown at a 4.4% compound annual growth rate (CAGR), from $829.42M to $1.03B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.